READOUT // 06 — FAQ
MOTS-c peptide: frequently asked questions
Direct answers, cited where quantitative, with the human-data gaps flagged rather than glossed.
What does the MOTS-c peptide do?
MOTS-c is a 16-amino-acid mitochondrial-derived peptide whose best-characterized action is inhibiting the folate cycle to raise AICAR and activate AMPK [1]. That improves glucose handling and insulin sensitivity in skeletal muscle in animal models, and it underlies the metabolic and exercise-mimetic effects reported in mice [1][2].
What is MOTS-c?
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide, sequence MRWQEMGYIFYPRKLR, encoded within the mitochondrial 12S rRNA gene (MT-RNR1) [1]. It is a mitochondrial-derived peptide, distinct from humanin and the SHLPs, and is detectable in human plasma and skeletal muscle [4].
How does MOTS-c work?
It inhibits the folate cycle and de novo purine biosynthesis, accumulating AICAR and activating AMPK [1]. Under metabolic stress it translocates to the nucleus and regulates NRF2/ARE genes [3], and a 2024 study identified casein kinase 2 (CK2) as a direct molecular target [9].
What is the amino-acid sequence and structure of MOTS-c?
MOTS-c is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR (molecular weight ~2174.61 Da), encoded by a short open reading frame within the mitochondrial 12S rRNA gene (MT-RNR1) [1]. The sequence is highly conserved across mammalian species, which is one reason researchers treat it as a functionally important signal rather than a coincidental product of the mitochondrial genome [4].
What are the negative side effects of MOTS-c?
No completed human safety trials exist, so a validated side-effect profile has not been established [4]. All tolerability data come from animal studies, and research-chemical purity, identity, and sterility vary by supplier because the material is not regulated as a pharmaceutical.
Is MOTS-c legal to buy?
MOTS-c is not approved by the FDA for any human use and is sold only as a research chemical for laboratory use [18]. It has no approved indication or formulation, and it is named on the FDA PCAC agenda for July 23–24, 2026 only as a substance under evaluation [18].
How often do you inject MOTS-c?
There is no human dosing schedule [4]. Published in-vivo work used daily or thrice-weekly intraperitoneal injection in rodents — for example, 15 mg/kg/day or 15 mg/kg 3×/week in the exercise-capacity study [2], and 0.5–5 mg/kg/day in the metabolic work [1]. Those are research-design frequencies in mice and cannot be extrapolated to humans.
Can MOTS-c cause weight gain?
In mouse studies MOTS-c prevented diet-induced obesity and improved metabolic homeostasis rather than promoting weight gain [1]. In the same work it increased thermogenic activation in adipose tissue [1]. There are no human interventional data on body weight, so weight effects in people remain unestablished [4].
Is MOTS-c hard on the liver?
No human hepatic-safety data exist for MOTS-c [4]. The published literature reports no validated human safety profile, so any organ-effect claim — including on the liver — would be speculative rather than evidence-based. All tolerability data to date come from animal studies, not human trials [4].
What are the downsides of MOTS-c?
The main limitations are the absence of human efficacy and safety trials, no validated human pharmacokinetics, unregulated research-chemical purity, and anti-doping prohibition for athletes [4]. Reported effects also vary by genotype and ancestry, so they are not uniform across populations.
Can I get MOTS-c over the counter?
No. MOTS-c is not an approved drug or dietary supplement and is not available over the counter [18]. It is sold only for laboratory research, with no approved human formulation or indication. It is currently named on the FDA PCAC agenda for July 23–24, 2026 as a substance under evaluation — not as an approved or over-the-counter product [18].
How long does it take for MOTS-c to kick in?
No human onset timeline has been established [4]. In rodent studies a single dose improved acute exercise performance, while metabolic benefits such as improved insulin sensitivity emerged over weeks of repeated dosing [1][2]. That is rodent timing from controlled experiments, not human guidance, and it should not be read as an expected effect in people.
Where is best to inject MOTS-c?
Research used intraperitoneal injection — into the abdominal cavity — in rodents, plus subcutaneous routes in some research contexts [1][2]. Those are laboratory administration methods chosen for animal experiments. No human injection-site guidance exists in the published literature, and none is provided here [4].
What are the potential benefits of MOTS-c?
Reported in animal and biomarker studies: improved insulin sensitivity and glucose handling, enhanced physical capacity (an exercise-mimetic effect), muscle-atrophy resistance, and associations with healthy aging [1][2][9]. A 2016 study also reported reduced bone loss in ovariectomized mice [7]. These are research findings in models, not demonstrated human outcomes [4].
How does MOTS-c make you feel?
There are no human experiential or subjective-effect data in the published literature [4]. All evidence is from animal models and observational human biomarker cohorts [10], which measure things like circulating peptide levels and metabolic markers — not how a person feels. Any subjective-effect claim is therefore unsupported by the research record.
How long does MOTS-c take to work?
No human timeline is established [4]. In rodents, metabolic effects developed over multi-week dosing — chronic studies ran roughly 8 weeks [1] — while an acute single-dose performance effect was observed in exercise studies [2]. Those rodent timeframes are research-design parameters, not predictions for people.
Does MOTS-c burn fat?
In mice, MOTS-c increased adipose thermogenic activation and prevented diet-induced obesity, working through AMPK in skeletal muscle [1]. But there are no human fat-loss trials, so a "fat-burning" claim in people is not supported by the literature [4]. The metabolic findings remain animal-model results.
Can I inject MOTS-c every day?
Daily intraperitoneal dosing was used in some rodent studies — for example, 0.5 mg/kg/day chronically [1] and 15 mg/kg/day in exercise work [2] — but no human dosing schedule has been validated. Nothing about a human frequency should be inferred from these animal protocols [4].
How long should you take MOTS-c?
No human treatment duration exists [4]. Rodent studies ran from days to several weeks — about 8 weeks for the chronic metabolic work [1] and 12 weeks in the bone study [7] — which reflects experimental design choices, not human guidance. There is no validated regimen for people, and none is implied here.
Is MOTS-c bad for the liver?
No human hepatic data are available for MOTS-c [4]. The published record reports no validated human safety profile of any kind, so liver-effect claims cannot be substantiated either way. Tolerability evidence to date comes only from animal studies, and research-chemical purity varies by supplier [4].
Where can I buy MOTS-c peptide online in the USA?
MOTS-c is sold only as a research chemical for laboratory use and is not an approved drug or supplement [18]. This site does not sell it and does not recommend vendors; it is an editorial digest of the research record.
Is MOTS-c legal?
MOTS-c is not an FDA-approved drug and is sold only as a research chemical for laboratory use [18]. It is named on the FDA PCAC agenda for July 23–24, 2026 as a substance under evaluation for the 503A bulks list — a scheduled discussion, not a ruling [18].
Can you get MOTS-c from a compounding pharmacy?
A 503A compounder may use a bulk substance only if it has a USP/NF monograph, is a component of an approved drug, or is on FDA's 503A bulks list [16]. MOTS-c is none of these today; it is under PCAC evaluation, not yet on the list [18].
What is the FDA 503A status of MOTS-c?
MOTS-c is not on FDA's final 503A bulks list; it is a research peptide that FDA has scheduled for PCAC evaluation at the July 23–24, 2026 meeting [18]. The audited FDA record does not assign it a numbered 503A category — its status is "under evaluation" [16][18].